VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

CCPS-P64kR N. meningitidis DNA vaccine P3A N. meningitidis ExbB Protein Vaccine N. meningitidis LctP Protein Vaccine N. meningitidis NspA Protein Vaccine N. meningitidis TbpA Protein Vaccine N. miningitidis TBP2 Protein Vaccine Neisseria meningitidis metH/siaD mutant vaccine Neisseria meningitidis rfaF/siaD mutant vaccine
Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004165
  • Type: Conjugate vaccine
  • Status: Research
  • lpdA gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: aluminum hydroxide vaccine adjuvant
  • Immunization Route: Not specified
  • Vaccine Ontology ID: VO_0004569
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • Antigen: a T-cell helper epitope and a peptide mimic of N. meningitidis serogroup C (Prinz et al., 2003)
  • gp120 gene engineering:
    • Type: DNA vaccine construction
    • Description: The T-cell epitope used was from HIV gp120 (Prinz et al., 2003).
    • Detailed Gene Information: Click Here.
  • Vector: pcDNA3.1 (Prinz et al., 2003)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004011
  • Type: Subunit vaccine
  • Status: Research
  • ExbB gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Subcutaneous injection
  • Vaccine Ontology ID: VO_0004012
  • Type: Subunit vaccine
  • Status: Research
  • lctP gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Subcutaneous injection
  • Vaccine Ontology ID: VO_0004013
  • Type: Subunit vaccine
  • Status: Research
  • NspA from N. meningitidis MC58 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: QuilA vaccine adjuvant
    • VO ID: VO_0001263
    • Description: QuilA (CedarLane Laboratories, Hornby, Ontario, Canada) (Martin et al., 1997).
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0004064
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: rTbpA
  • tbpA gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
    • VO ID: VO_0000139
    • Description: Vaccines were prepared with an equal volume of either Freund's complete adjuvant (first immunization) or Freund's incomplete adjuvant (subsequent immunizations) (West et al., 2001).
  • Adjuvant: incomplete Freunds adjuvant
    • VO ID: VO_0000142
    • Description: Vaccines were prepared with an equal volume of either Freund's complete adjuvant (first immunization) or Freund's incomplete adjuvant (subsequent immunizations) (West et al., 2001).
  • Immunization Route: subcutaneous injection
  • Vaccine Ontology ID: VO_0004014
  • Type: Subunit vaccine
  • Status: Research
  • tbp2 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: aluminum hydroxide vaccine adjuvant
  • Immunization Route: Subcutaneous Injection
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • metH gene engineering:
    • Type: Gene mutation
    • Description: This metH/siaD mutant is from Neisseria meningitidis (Li et al., 2004).
    • Detailed Gene Information: Click Here.
  • siaD gene engineering:
    • Type: Gene mutation
    • Description: This metH/siaD mutant is from Neisseria meningitidis (Li et al., 2004).
    • Detailed Gene Information: Click Here.
  • siaD gene engineering:
    • Type: Gene mutation
    • Description: This metH/siaD mutant is from Neisseria meningitidis (Li et al., 2004).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • rfaF gene engineering:
    • Type: Gene mutation
    • Description: This rfaF/siaD mutant is from Neisseria meningitidis (Li et al., 2004).
    • Detailed Gene Information: Click Here.
  • siaD gene engineering:
    • Type: Gene mutation
    • Description: This rfaF/siaD mutant is from Neisseria meningitidis (Li et al., 2004).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intraperitoneal injection (i.p.)
Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Two experiments were carried out; in both cases mice were immunized with 2.5 μg of either plain or conjugated CCPS, and Al(OH)3 as adjuvant. Two doses were given 15 days apart and 7 days after the last dose mice were bled, sera were stored at −20°C. In the first experiment four groups of 10 mice each were immunized with the following immunogens: CCPS–P64kR, CCPS–P64kC, carrier protein P64k, and plain polysaccharide. For the second experiment, four groups of 10 mice each were immunized with the three conjugates obtained from different size polysaccharides using the reductive amination method and with plain CCPS as control (Carmenate et al., 2004).
  • Challenge Protocol: Sera of immunized mice was used in rats to detect an immune response (Carmenate et al., 2004).
  • Efficacy: Sera of the challenge group immunized with CCPS-P64kR showed a three-fold higher bactericidal response than the sera of the group immunized with the plain CCPS and they were able to protect against challenge with Neisseria meningococci in the infant rat protection model (Carmenate et al., 2004).

Mouse Response

  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Mice immunized with P3A DNA produced an anti-MCPS IgM antibody response that was significantly higher (P < 0.05) than that of mice immunized with P3C DNA (negative control) (Prinz et al., 2003).
  • Efficacy: Mice immunized with P3A DNA were protected against meningococcal infection, with 100% survival. Five of the six mice immunized with P3C DNA (negative control) died within 24 hr postchallenge (Prinz et al., 2003).

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: To examine the protective efficacy of recombinant proteins, adult mice (6-week-old, female BALB/c animals, 35 per group) were immunised on days 1 and 21 with 25 μg of antigen given by subcutaneous (s.c.) injection. Each protein was mixed with Freund's incomplete adjuvant (50% v/v) prior to administration. Mice in control groups were immunised with adjuvant alone or recombinant homologous PorA prior to challenge (Sun et al., 2005).
  • Challenge Protocol: 28 days after immunization, animals were challenged with live bacteria at either a high (107 CFU, 15 mice) or low (106 CFU, 15 mice) dose of MC58 (Sun et al., 2005).
  • Efficacy: ExbB, which is required for iron acquisition, elicited protective immunity and was able to protect mice from bacterial challenge (Sun et al., 2005).

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: To examine the protective efficacy of recombinant proteins, adult mice (6-week-old, female BALB/c animals, 35 per group) were immunised on days 1 and 21 with 25 μg of LctP given by subcutaneous (s.c.) injection. Each protein was mixed with Freund's incomplete adjuvant (50% v/v) prior to administration. Mice in control groups were immunised with adjuvant alone or recombinant homologous PorA prior to challenge (Sun et al., 2005).
  • Challenge Protocol: 28 days after immunization, animals were challenged with live bacteria at either a high (107 CFU, 15 mice) or low (106 CFU, 15 mice) dose of MC58 (Sun et al., 2005).
  • Efficacy: LctP which is required for iron acquisition, elicited protective immunity and was able to protect mice from bacterial challenge (Sun et al., 2005).

Mouse Response

  • Vaccination Protocol: Groups of mice were injected three times at 3-wk intervals with 10 or 20 μg of affinity-purified NspA recombinant protein and 25 μg of QuilA (CedarLane Laboratories, Hornby, Ontario, Canada) as the adjuvant. Control mice were injected with either 20 μg of BSA (Sigma), concentrated E. coli BL21(DE3) supernatant, or PBS. 2 wk after the third injection the mice were used for the protection experiments (Martin et al., 1997).
  • Challenge Protocol: For inoculation of mice, meningococci were removed from the chocolate agar plates after ∼20 h of incubation and suspended in PBS and injected into mice (Martin et al., 1997).
  • Efficacy: 80% of the mice immunized with three injections of either 10 or 20 μg of purified recombinant meningococcal NspA protein survived the bacterial challenge comparatively to 0 to 20% in the control groups. Survivors at 72 h did not succumb during an additional two weeks of observation. The mice in the control group injected with concentrated E. coli culture supernatant were not protected against the bacterial challenge indicating that the components present in the culture media and other E. coli antigens that might be present in small amounts after purification do not contribute to the observed protection against N. meningitidis (Martin et al., 1997).

Mouse Response

  • Host Strain: NIH
  • Vaccination Protocol: Each mouse received 0.2 ml, containing 10 μg of rTbpA protein and Freund's complete adjuvant, by subcutaneous injection. All animals were immunized on days 1, 21, and 28 (West et al., 2001).
  • Challenge Protocol: Mice were infected by intraperitoneal injection of N. meningitidis at several challenge doses (West et al., 2001).
  • Efficacy: 100% protection was afforded by vaccination with rTbpA at the 2 × 107 CFU challenge dose andat the 2 × 108 CFU challenge dose, the rTbpA-vaccinated group had an 85% survival rate (West et al., 2001).

Mouse Response

  • Vaccination Protocol: Groups of 48 mice were immunized subcutaneously on days 0, 21, and 35 with different vaccine preparations containing 5 mg of protein adsorbed onto 0.1 mg of aluminum hydroxide per 0.5 ml; PBS containing aluminum hydroxide and heat-inactivated N. meningitidis B16B6 were used as controls (Lissolo et al., 1995).
  • Challenge Protocol: 41 days after immunization, mice within a group were subdivided into groups of eight, and each subgroup received by the intraperitoneal route 24 mg of iron-loaded hTf (Sigma) and, immediately after by the intraperitoneal route, 0.5 ml of N. meningitidis grown under iron restriction. The bacterial load varied from 104 to 108 CFU. Mortality rates were measured for 5 days following challenge (Lissolo et al., 1995).
  • Efficacy: Mice immunized with purified Tbp2 survived a lethal challenge to a similar degree as animals immunized with the Tbp1-Tbp2 complex, demonstrating that Tbp2 played an important role in the protective activity observed with the complex, eliciting antibodies that are not only bactericidal but also inhibitory for meningococcal growth (Lissolo et al., 1995).

Mouse Response

  • Persistence: A metH/siaD mutant is attenuated in mice (Li et al., 2004).
  • Efficacy: A metH/siaD mutant induces significant protection in mice from challenge with wild type neisseria meningitidis (Li et al., 2004).

Mouse Response

  • Persistence: A rfaF/siaD mutant is attenuated in mice (Li et al., 2004).
  • Efficacy: An rfaF/siaD mutant induces significant protection in mice from challenge with wild type Neisseria meningitidis (Li et al., 2004).

Rat Response

  • Vaccination Protocol: Rat pups, aged 5 or 6 days, were injected i.p. with 100 μl of sera ( from immunized mice) previously diluted 1:10 and ferric dextran (Carmenate et al., 2004).
  • Challenge Protocol: One hour after immunization, infant rats were challenged with 107 cfu of meningococcal strain Z4181. The development of bacteremia was assessed by culturing the blood samples taken 4 h after challenge (Carmenate et al., 2004).
  • Efficacy: Sera of the challenge group of mice immunized with CCPS-P64kR showed a three-fold higher bactericidal response than the sera of the group immunized with the plain CCPS and they were able to protect against challenge with Neisseria meningococci in the infant rat protection model (Carmenate et al., 2004).
References References References References References References References References References
Carmenate et al., 2004: Carmenate T, Canaán L, Alvarez A, Delgado M, González S, Menéndez T, Rodés L, Guillén G. Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates. FEMS immunology and medical microbiology. 2004; 40(3); 193-199. [PubMed: 15039094].
Prinz et al., 2003: Prinz DM, Smithson SL, Kieber-Emmons T, Westerink MA. Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide. Immunology. 2003; 110(2); 242-249. [PubMed: 14511238].
Sun et al., 2005: Sun Y, Li Y, Exley RM, Winterbotham M, Ison C, Smith H, Tang CM. Identification of novel antigens that protect against systemic meningococcal infection. Vaccine. 2005; 23(32); 4136-4141. [PubMed: 15964482].
Sun et al., 2005: Sun Y, Li Y, Exley RM, Winterbotham M, Ison C, Smith H, Tang CM. Identification of novel antigens that protect against systemic meningococcal infection. Vaccine. 2005; 23(32); 4136-4141. [PubMed: 15964482].
Martin et al., 1997: Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. The Journal of experimental medicine. 1997; 185(7); 1173-1183. [PubMed: 9104804].
West et al., 2001: West D, Reddin K, Matheson M, Heath R, Funnell S, Hudson M, Robinson A, Gorringe A. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infection and immunity. 2001; 69(3); 1561-1567. [PubMed: 11179327].
Lissolo et al., 1995: Lissolo L, Maitre-Wilmotte G, Dumas P, Mignon M, Danve B, Quentin-Millet MJ. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infection and immunity. 1995; 63(3); 884-890. [PubMed: 7868259].
Li et al., 2004: Li Y, Sun YH, Ison C, Levine MM, Tang CM. Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci. Infection and immunity. 2004; 72(1); 345-351. [PubMed: 14688114].
Li et al., 2004: Li Y, Sun YH, Ison C, Levine MM, Tang CM. Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci. Infection and immunity. 2004; 72(1); 345-351. [PubMed: 14688114].